3 out of 4 patients pay $0 due to excellent coverage and assistance
Industry-leading accuracy so you can feel confident in your results
Unlike some labs, Myriad protects your personal information
Myriad makes genetic testing simple with clear, actionable results
MyRisk™ Hereditary Cancer Test is a multi-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on 11 primary cancer sites.
Precise™ Tumor is a next-generation sequencing (NGS) assay with hybrid capture model consisting of DNA- and RNA-based testing which detects Single-Nucleotide Variants (SNV), Insertion-Deletion Mutations (INDELs), Copy Number Variants (CNV), and fusions in solid tumors.
Making a decision on treatment options for patients diagnosed with early-stage breast cancer is an important choice and one that should be made with the best information possible. EndoPredict® can help accurately determine an individual patient’s 10-year risk of recurrence to help physicians identify which patients may consider safely forgoing chemotherapy.
BRACAnalysis CDx® is an FDA-approved laboratory developed test for BRCA1 and BRCA2 intended to inform patient management related to the PARP inhibitors, Lynparza® (olaparib) and Zejula® (niraparib).1,2,3
MyChoice® CDx is the first and only FDA-approved tumor test that determines HRD status using BRCA status and Genomic Instability Status.
Prolaris® is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness.
Myriad believes in affordable testing for patients who meet guidelines for testing. Through excellent insurance coverage and programs such as the Myriad Financial Assistance Program, providers and patients can feel confident knowing Myriad has multiple options tailored to each patient’s situation.
Myriad Oncology believes in providing the most accurate and highest quality tests for patients. From hereditary cancer to precision medicine, our tests are designed to give providers and patients the most accurate answer possible.
With our hereditary cancer tests, we make a lifetime commitment to patients to ensure that information does not stop after the results are delivered. As the science of genetics continues to evolve, Myriad is constantly reviewing and evaluating new developments, and any new findings that may impact patients are always delivered to both the provider and patient to maintain the highest quality of patient care possible.
Myriad Oncology believes that results and genetic information belongs to the patient. We take several steps to ensure that the security and privacy of patient data is not compromised. We believe that patients should be in control of their information.
Myriad Oncology knows that the field of genetics can be complex, but we have taken steps to ensure that both providers and patients are able to understand the results and further treatment options based on national medical guidelines. The MyRisk Medical Management Tool enables patients to share this vital information with their families in order to have all of your loved ones aware of any potential risks they may face. Patients who receive a test from Myriad Oncology can feel empowered to know that their results can be a meaningful piece of developing a prevention or treatment plan.